Noselab

📍 München, Germany🗓 Founded 2020👥 22 employees💰 Last funded 2023
Medical Equipment Manufacturing
LinkedIn
Welcome to Noselab. With its rapidly increasing number of patients, Alzheimers is considered as one of the most common diseases worldwide. So far, the diagnosis of Alzheimers is complex, expensive and happens at a later stage in the course of the disease. That’s why early detection is one, if not the key component for coming up with better and more effective treatments. We are focusing on the nose as interface to our frontal brain and we are targeting the challenges of Alzheimers by developing a novel, ground-breaking test based on the analysis of nasal secretion to support the diagnosis. We complement this diagnostic solution with a data-driven medicine approach leveraging AI-based methods to generate insights to improve personalised treatments and drug development. Our vision is to drive a paradigm shift in diagnosis, understanding and treatment of Alzheimers to significantly improve patients’ lives. Interested to join our team? Contact us.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Noselab?
Noselab has 1 investors on record on gritt.io, 1 mid-stage.
When did Noselab last raise funding?
The most recent investment in Noselab recorded on gritt.io was in 2023.
When was Noselab founded?
Noselab was founded in 2020.
What industry is Noselab in?
Noselab operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Noselab based?
Noselab is headquartered in München, Germany.